Prognostic value of 6-minute walk test in stable outpatients with heart failure

Area of Science:

• Cardiology
• Clinical Medicine
• Prognostics

Background:

• Heart failure (HF) is a major cause of morbidity and mortality.
• Accurate prognostic markers are crucial for managing stable outpatients with HF.
• The 6-minute walk test (6MWT) is a functional capacity assessment tool.

Purpose of the Study:

• To evaluate the prognostic value of the 6-minute walk test (6MWT) in stable outpatients with heart failure.
• To determine if 6MWT distance predicts cardiac death in this population.

Main Methods:

• Prospective study of 43 stable heart failure patients (New York Heart Association class II/III) with left ventricular systolic dysfunction (ejection fraction ≤0.40).
• Patients underwent baseline 6-minute walk test (6MWT) and echocardiography.
• Patients were divided into two groups based on 6MWT distance (<300 m vs. >300 m) and followed for 2 years for cardiac death.

Main Results:

• A 6-minute walk test (6MWT) distance of ≤300 m was associated with a significantly higher mortality rate (79% vs. 7%, P <0.001).
• Patients with a 6MWT distance ≤300 m had a significantly higher death risk (P=0.005).
• Lower left ventricular ejection fraction (≤0.30) also correlated with increased death risk (P=0.02).

Conclusions:

• A 6-minute walk test (6MWT) distance of ≤300 m is a simple and effective prognostic marker for cardiac death in mild-to-moderate heart failure.
• The 6MWT provides valuable prognostic information beyond traditional measures like ejection fraction.
• This test can aid in risk stratification and clinical decision-making for heart failure patients.